8-K: Olema Oncology Renames, Relocates Principal Offices

Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) announced its corporate name change and relocation of principal executive offices, effective November 12, 2026.

Summary

• Olema Oncology, Inc., formerly Olema Pharmaceuticals, Inc., has officially changed its corporate name.
• The name change was effected by filing an Eighth Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware.
• The change became effective on November 12, 2026, at 4:01 p.m. Eastern Time.
• Stockholder approval was not required for this name change under Delaware General Corporation Law.
• The company's common stock will continue to trade on The Nasdaq Global Select Market under the ticker symbol OLMA.
• The company has also relocated its principal executive offices from San Francisco to South San Francisco, California.
• This filing also includes amendments to the company's Bylaws to reflect the name change.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, primarily reflecting an administrative and branding change rather than a fundamental shift in business operations or financial performance.

Positives

• The name change to Olema Oncology, Inc. may better reflect the company's focus on oncology, potentially enhancing brand recognition within its target market.
• The company's common stock will continue to trade under the familiar ticker symbol OLMA, minimizing disruption for investors.
• The relocation to South San Francisco may offer strategic advantages, potentially closer proximity to biotech hubs or improved facilities.

Negatives

• The filing does not contain any new financial results or operational updates, making it difficult to assess any immediate impact on the company's performance.
• The name change and relocation are administrative actions and do not inherently improve the company's clinical pipeline or commercial prospects.

Risks

• While not explicitly stated as a risk, any confusion or lack of awareness regarding the name change could potentially impact investor relations or market perception.
• The relocation of principal executive offices could involve unforeseen costs or operational disruptions during the transition period.

Future Outlook

The filing does not contain any forward-looking statements or guidance. It solely pertains to administrative changes.

Management Comments

• The company's common stock will continue to be listed and trade on the Nasdaq Global Select Market under the ticker symbol OLMA.
• Stock certificates reflecting the prior corporate name will continue to be valid.

Industry Context

StockSavvy.ai notes that corporate name changes are common in the biopharmaceutical industry, often occurring to better align branding with a company's evolving strategic focus, therapeutic areas, or pipeline development. This move by Olema Oncology is consistent with industry practices as companies mature and refine their market positioning.

Corporate Governance

Stakeholder Impact

• Shareholders: No immediate impact expected as stock will continue to trade under the same ticker symbol (OLMA). Stock certificates remain valid.
• Employees: May experience operational adjustments related to the office relocation.
• Investors: May need to update their records to reflect the new corporate name.
• Suppliers/Creditors: Should update their records with the new company name and address.

Next Steps

• Continue trading on The Nasdaq Global Select Market under the ticker symbol OLMA.
• Operate from the new principal executive office location in South San Francisco.

Key Dates

Keywords

Olema Oncology, Olema Pharmaceuticals, Name Change, Corporate Relocation, Delaware, Nasdaq, Biopharmaceutical, Oncology